The Patent Finder

Kissei Pharmaceutical Co., Ltd.

24 patents currently held · Updated Nov 18, 2026
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 6 name spellings.

6
Ending by 2030
Jun 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Mar 19 to 22, 2027 · next Mar 19
  • 1 fee due Apr 27, 2027
    The maintenance fee for Salt of fused heterocyclic derivative and crystal thereof (US 9,169,266) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
  • 2 fees due Sep 1 to 3, 2027 · next Sep 1
  • 2 fees due Nov 12 to 14, 2027 · next Nov 12

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,834,193Indoline compound and process for producing the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,003,647(AZA)INDOLE Derivative and Use Thereof for Medical Purposes
In force
 · High confidence
In forceHigh confidence
US 8,993,616(AZA)INDOLE Derivative and Use Thereof for Medical Purposes
In force
 · Low confidence
In forceLow confidence
US 8,399,418Monosebacate of pyrazole derivative
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,426,427Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,040,693Fused Heterocyclic Derivative, Medicinal Composition Containing the Same, and Medicinal Use Thereof
In force
 · High confidence
In forceHigh confidence
US 9,737,539Salt of fused heterocyclic derivative and crystal thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,016,433Salt of fused heterocyclic derivative and crystal thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,576,084Salt of fused heterocyclic derivative and crystal thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,169,266Salt of fused heterocyclic derivative and crystal thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 24 patents shown.
Pro members see all 24.
Pro members: see all 24 patents
Also on record, not counted in the 24: 5 patents in force now held by others · 92 lapsed for an unpaid fee · 60 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 1 abandoned · 39 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited